The attenuation of the Sabin type 3 oral poliovirus vaccine is driven by only two specific point mutations.
Answers are grounded in this paper and cite their sources.
Supports minimal mutational basis for Sabin 3 attenuation in models; leaves open translation to human vaccine performance.
The poliovirus type 3 Sabin oral poliovirus vaccine strain P3/Leon/12a1b differs in nucleotide sequence from its neurovirulent progenitor P3/Leon/37 by just 10 point mutations. The contribution of each mutation to the attenuation phenotype of the vaccine strain was determined by the construction of a series of recombinant viruses from infectious cDNA clones. The neurovirulence testing of recombinant viruses indicated that the attenuation phenotype is determined by just two point mutations: a C to U in the noncoding region at position 472 and a C to U at nucleotide 2034 which results in a serine-to-phenylalanine amino acid substitution in the structural protein VP3.
No takes yet. Share an insight, caveat, or question.
Westrop et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: